Brimonidine, timolol
Sold as Brimoct co, Combigan
Combination product
This product contains more than one active ingredient, so it has no single molecular structure.
Background
Registration
- Applicants
- 2
- Registrations
- 2
Applicants and registrations
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Brimoct co Each 1 ml of solution contains BRIMONIDINE TARTRATE 2,0 mg TIMOLOL 5,0 mg | Not listed | 49107949/15.4/1079 | Registered | Not determined | None |
| Combigan EACH 1,0 ml SOLUTION CONTAINS :BRIMONIDINE TARTRATE 2,0 mg, TIMOLOL MALEATE EQUIVALENT TO TIMOLOL 5,0 mg | 2 mg/ml + 5 mg/mlOphthalmic solution | A390464A39/15.4/0464Approved 17 February 2025 | Registered | Not determined | PIPIL |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S3: Brimonidine
Consolidated Schedules 06 July 2026, line 3233
S3: Timolol
Consolidated Schedules 06 July 2026, line 4325
10 of 19 approved products with this ingredient carry S4 on their leaflet.
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
SAHPRA documents
These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.